Skip to content

Exploring the Difference Between Gastric Cardia Cancer and Non-cardia Gastric Cancer Based on Multiomics

Exploring the Difference Between Gastric Cardia Cancer and Non-cardia Gastric Cancer Based on Multiomics

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05812287
Enrollment
120
Registered
2023-04-13
Start date
2024-03-14
Completion date
2028-12-01
Last updated
2026-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stomach Neoplasm

Brief summary

This is an observational study with a case control design. This study included patients with gastric cancer confirmed by pathological diagnosis of gastric tissue, and matched the control population according to age, gender, etc. In this study, researchers collected clinical information and multiple biological samples such as saliva, serum, tissue,and feces from the study subjects. We combined multi-omics approach to explore the differences between gastric cardia cancer and non-cardia gastric cancer for early screening of gastric cancer.

Interventions

OTHERDetection of biological samples based on multi-omics analysis

In this study, we combined multi-omics analysis to study the changes of various samples such as feces, serum, and saliva, and screen key differential markers.

Sponsors

Qilu Hospital of Shandong University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Study population signing informed consent form * Age: 18-75 years old * The study population must underwent endoscopic examination and was confirmed by pathological diagnosis as gastric cancer: including high-level intraepithelial neoplasia, early gastric cancer, and advanced gastric cancer.

Exclusion criteria

* Those who have undergone gastrointestinal surgery within the past 1 year; Patients who have undergone neoadjuvant chemotherapy and have developed tumors in the residual stomach after previous partial gastrectomy. * Those who have used proton pump inhibitors, antibiotics, probiotics, and prebiotics daily within the past month, and those who have recently received hormone therapy. * People with infectious diseases and other digestive system diseases that interfere with the experimental results, such as inflammatory bowel disease, irritable bowel syndrome, etc.

Design outcomes

Primary

MeasureTime frameDescription
Early gastric cancer detection rate36 monthsThis study combines multi-omics approach to explore the differences between tumor cohorts and healthy controls, and to assist in screening for early gastric cancer.

Countries

China

Contacts

CONTACTMiaomiao Ma, Bachelor
mmiao6098@163.com(86)17657686098

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 9, 2026